8-K current report · filed Nov 5, 2026

Keros Therapeutics, Inc. (KROS) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1KROS overview

Short answer

Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results and recent business highlights announced for the quarter ended September 30, 2026.

Keros Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results and recent business highlights announced for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed results and operational updates relevant to investors

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net income $14.2M, or $0.71 basic EPS, versus $7.3M loss, driven by $40.0M license revenue
  • Nine-month net loss $38.3M despite $40.0M license revenue, highlighting continued operating losses without partnering income
  • Rinvatercept Phase 2 DMD trial dosed its first patient, with initial data expected in the first half of 2027
  • KER-206 nominated for further investigation, expanding Keros’ pipeline into bone-loss disorders
  • Cash $259.5M, down from $287.4M at December 31, 2025, with runway projected into the second half of 2028

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Keros Therapeutics, Inc. 8-K filings

Get the next KROS 8-K as it lands

Follow KROS for push alerts, or ask the research agent what this filing means.